South Korea’s Hanmi Pharma starts sales of locally developed NSCLC drug

Starting line

Seoul-based Hanmi Pharmaceutical has started sales of non-small cell lung cancer therapy Olita--a drug developed locally that is licensed outside the country to ZAI Lab and Germany's Boehringer Ingelheim.

Olita (olmutinib), the Korea Herald reports, was approved in South Korea earlier this month for patients that have locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive NSCLC and have previously received an EGFR tyrosine kinase inhibitor therapy.

The drug, formerly candidate HM61713, was part of a KRW850 billion ($730 million) exclusive license agreement with the private pharmaceutical company Boehringer last year, providing worldwide exclusive rights (except in Korea, China and Hong Kong). Meanwhile, Chinese ZAI Lab won exclusive rights in China, including Hong Kong and Macau.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Hanmi has been at the center of series of high-profile licensing deals since 2015, including with Eli Lilly ($LLY), Sanofi ($SNY) and the Johnson & Johnson ($JNJ) unit Janssen Pharmaceuticals.

In April, the company announced a major expansion in China that would see about $200 million invested in the Shandong province on a greenfield manufacturing plant and R&D center, which is expected to be finished in 2026 and is set to make chemosynthetic and biological drugs, as well as health foods.

- here's the story from the Korea Times

Read more on

Suggested Articles

Glenmark hopes to raise cash from selling drugs outside of its focus therapeutic areas and from finding new investors for its API and innovation spinoffs.

Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.

There are five or six potential deals similar to Takeda's mooted European sale Stada could go after, CEO Peter Goldschmidt said.